GLSI stock forecast, quote, news & analysis
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences... Show more
Greenwich LifeSciences (GLSI) Stock Analysis: Phase III Trial Momentum Builds
Key Takeaways
- GLSI shares have shown volatility in recent trading sessions, driven by FLAMINGO-01 trial updates and FDA approvals.
- FDA clearance for commercial GP2 in the ongoing Phase III breast cancer trial marks a key manufacturing milestone.
- Cash position strengthened to approximately $12.5 million, supporting trial advancement amid rising burn rates.
- Analysts maintain Buy ratings with price targets around $47.50, citing trial efficacy data.
- Directors and officers extended share lock-up to September 2026, signaling long-term alignment.
Current Market Snapshot
Greenwich LifeSciences (GLSI) stock has navigated volatile waters in recent weeks, reflecting progress in its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy targeting HER2-positive breast cancer recurrence. Shares reached a 52-week high amid positive regulatory nods but pulled back amid broader biotech sector pressures and trial-related cash updates. Trading volume has spiked around key announcements, underscoring investor focus on clinical milestones. The stock's beta of 1.49 highlights its sensitivity to market swings, yet fundamentals tied to trial enrollment—over 1,000 patients screened—sustain interest. Market cap hovers near $350 million, positioning GLSI as a small-cap biotech play with high-risk, high-reward potential.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of top-performing AI-powered trading bots from a platform hosting hundreds of such agents that analyze and trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—from short-term scalping on 5- to 15-minute timeframes to sector-specific plays in semiconductors, aerospace, mining, and leveraged ETFs—adapting to current market conditions via continuous retraining on live data. Highlighted performers boast annualized returns ranging from +15% to over +290%, with win rates of 55% to 95% and low drawdowns, such as a volatility bot yielding +292.87% annualized on tickers like USAR and SMR, or semiconductor agents at +118.88% on SOXL. Only the most promising, real-time optimized bots earn a spot here, offering copy-trading signals with risk management. Investors may explore these tools to enhance strategies amid volatile biotech trends like GLSI.
Recent Developments Driving GLSI Price Action
Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical firm developing immunotherapies for HER2-positive breast cancer, has seen its stock price swing sharply in recent weeks, tied to pivotal updates on its Phase III FLAMINGO-01 trial evaluating GLSI-100 (GP2 + GM-CSF). The trial, spanning 150 sites in the U.S. and Europe with Fast Track designation, has screened over 1,000 patients, fueling optimism around enrollment pace and potential recurrence prevention.
On January 22, 2026, the company announced FDA approval for using commercially manufactured GP2 in FLAMINGO-01, a critical step validating scalability for late-stage production. This news triggered premarket gains exceeding 16%, as it de-risks commercialization paths post-positive Phase IIb data showing zero recurrences in certain cohorts after five years. Shares surged initially but moderated amid profit-taking.
Five days later, on January 27, Greenwich disclosed a preliminary cash update: ATM offerings raised about $7 million in early January, boosting balances to roughly $12.5 million from $6 million at year-end 2025, after a 2025 burn of $9.5 million. While affirming funding into 2026, projections of higher 2026-2027 burn rates introduced dilution concerns, contributing to subsequent pullbacks. The stock hit a 52-week high near $34 before retreating over 20% from peaks, reflecting biotech volatility.
Earlier, on December 29, 2025—just within the extended window—the board extended lock-ups for directors, officers, and pre-IPO investors to September 30, 2026, approximately 72 months post-IPO. This move, amid preliminary FLAMINGO-01 open-label data showing up to 80% recurrence reduction, reinforced management alignment but coincided with a $50 million market cap dip, frustrating recent insider buyers holding 53% stake.
Analyst actions amplified sentiment: HC Wainwright raised its target to $50 from $39 on December 30, 2025, citing expanded GLSI-100 efficacy in non-HLA-A*02 patients, potentially doubling addressable market. Noble Capital echoed Buy ratings. Consensus targets at $47.50 imply substantial upside, though a Sell from Weiss Ratings tempers views. No recent earnings were reported, with next due March 2026; TTM EPS stands at -1.46, typical for development-stage biotech. Macro factors like healthcare sector rotation and interest rate sensitivity pressured small-caps, yet trial catalysts dominated price behavior.
2026 Outlook and Key Factors to Monitor
As Greenwich LifeSciences advances through 2026, focus will center on FLAMINGO-01 milestones, including full enrollment toward 750 patients, interim data readouts, and Data Safety Monitoring Board reviews. Positive recurrence reduction signals from the open-label arm could broaden GLSI-100's applicability beyond HLA-A*02 patients, expanding the HER2-positive breast cancer market. Regulatory interactions, building on Fast Track status and GP2 manufacturing approval, may accelerate timelines toward potential BLA submission.
Financial runway is key, with current cash supporting operations but rising burn rates projected amid trial scaling. Ongoing ATM usage aims to bridge to 2027 without major dilution, though market conditions could influence execution. Competitive landscape in HER2 immunotherapies, evolving standards of care, and macroeconomic pressures on biotech funding warrant attention. Insider lock-ups through September underscore commitment, while analyst EPS estimates around -$1.21 for FY2026 reflect pre-revenue status. Investors should track patient retention, adverse event rates, and peer trial outcomes for balanced insights into long-term positioning.
GLSI in upward trend: 10-day moving average broke above 50-day moving average on May 19, 2026
The 10-day moving average for GLSI crossed bullishly above the 50-day moving average on May 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GLSI advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .
GLSI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 135 cases where GLSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for GLSI moved out of overbought territory on May 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where GLSI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on June 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLSI as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for GLSI turned negative on June 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
GLSI moved below its 50-day moving average on June 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLSI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GLSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GLSI's P/B Ratio (1000.000) is very high in comparison to the industry average of (21.430). P/E Ratio (0.000) is within average values for comparable stocks, (35.359). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.649). GLSI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (0.000) is also within normal values, averaging (362.782).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology